Operations and site lead for the SAMDI business unit within Charles River-Chicago. Led integration of the SAMDI Tech acquisition into the Charles River Labs broader corporate portfolio, with continued double digit revenue growth during the integration. Lead dozens of small molecule discovery projects for biotech and pharma clients in multinational collaborative settings. Responsible for growth of the site and expansion of technical capabilities around mass spectrometry and beyond.

Tango is an innovative phage display platform technology company that is transforming the landscape in antibody and antibody mimics for assay detection from research tools through diagnostics.

Co-founder of SAMDI Tech, acquired by Charles River Labs in 2023 for $65M. Built this profitable biotechnology company through a bootstrap model with no Founder or Venture funding. SAMDI Tech is a CRO that offers unique assay capabilities that are commercially available through a contract assay and drug discovery offering. The assay platform, SAMDI, combines mass spectrometry with surface chemistry and high-density arrays for rapid and quantitative measurement of analytes in biochemical reactions. Our approach to screening enzyme activities eliminates the caveats of labeled methodologies that include: reducing rates of false positives and negatives, shortening assay development times, and screening in a high-throughput format. SAMDI provides a better understanding of biological function and aids in the discovery of early stage enzyme modulators involved in human disease.

Co-founder of SAMDI Tech Inc. Oversees all business and scientific operations. Technical lead on over 70 target projects with 9 top 10 pharma and several small pharma/biotech clients. Projects range from enzyme kinetics through high throughput drug discovery, as well as hit follow up activities. Integral part of the SAMDI Tech business development team with over 200 technical presentations. Responsible for all accounting and financial functions. Manage a team of scientists that conducts mass spectrometry-based biochemical assays. PI on SBIR Phase I and II grants totaling over $800k.

Amunix Pharmaceuticals, acquired in 2022 by Sanofi for $1.2B, is an industry leader in the discovery and development of long-acting protein-based therapeutics and drug conjugation technologies. Amunix’ pipeline products are based on its proprietary XTEN® half-life extension, XDC drug-conjugate delivery and ProTIA pro-drug, bispecific T-cell engager platform technologies. Amunix is applying these advances in delivery technology over a wide range of therapeutic areas, delivering improved pharmaceutical safety, efficacy and dosing. The company is actively engaged in both a diverse array of internal product development efforts as well as ongoing collaborations with partnering companies.

Lead scientist in the development and commercialization of SAMDI, a label-free drug discovery platform for high throughput screening of biochemical assays. Integration of liquid handling processes to high density biochip arrays. Label-free assay development and enzyme substrate optimization for discovery of small molecule inhibitors. Secured non-dilutive funding to initiate a spin-out company.

Founding Scientist and Lead Molecular Biologist on several projects to extend half-life of existing biologics in blood using the revolutionary XTEN technology. Responsible for general business operations and management of personnel. Part of the Amunix team that licensed XTEN to a spin off, Versartis, which exited with an IPO in March 2014. Amunix was acquired in 2022 by Sanofi for $1.2B.

Lead phage display scientist and molecular biologist on several projects for the development of antibodies and affinity reagents. Developed cutting-edge phage display libraries and procedures for discovery of novel peptide ligands.

Scientific lead on pioneering whole-genome determination of essential genes in E. coli using transposon mutagenesis and PCR mapping. Identified several gene products as antimicrobial drug targets. Led several projects for characterizing synthesis of CoA, riboflavin, NAD, and isoprenoids.